Liver Cancer Therapeutics Market Size, Share & Segmentation, By Therapy Type (Immunotherapy, Targeted Drug Therapy, and Chemotherapy), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy), and by Regions Global Market Forecast 2023-2030

Liver Cancer Therapeutics Market Report Scope & Overview:

The Liver Cancer Therapeutics Market size was USD 2923.58 Million in 2022 and is expected to Reach USD 12910.02 Million by 2030 and grow at a CAGR of 20.4 % over the forecast period of 2023-2030.

The Liver Cancer Therapeutics Market refers to the pharmaceuticals and medical treatments used for the management and treatment of liver cancer. Hepatocellular carcinoma (HCC), often known as liver cancer, is a kind of cancer that begins in the liver cells. It is a significant health concern globally and is associated with high mortality rates. The liver cancer therapeutics market includes various treatment options such as surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy, and liver transplantation. The choice of treatment depends on several factors, including the stage of cancer, the overall health of the patient, and the availability of resources. The market for liver cancer therapeutics has been growing due to the increasing incidence of liver cancer worldwide. Risk factors for liver cancer include chronic hepatitis B and C infections, cirrhosis (scarring) of the liver, excessive alcohol consumption, obesity, and exposure to certain toxins and chemicals. The market is driven by advancements in medical research and technology, which have led to the development of innovative therapies targeting liver cancer. Additionally, the rising awareness about early detection and diagnosis of liver cancer has contributed to the market growth.

To get more information on Liver Cancer Therapeutics Market - Request Free Sample Report

However, the liver cancer therapeutics market also faces challenges such as high treatment costs, side effects associated with therapy, and limited effectiveness of existing treatment options in advanced stages of the disease. These factors highlight the need for ongoing research and development efforts to improve treatment outcomes and develop more targeted and personalized therapies. It's important to note that the specific market size and dynamics of the liver cancer therapeutics market can vary over time and across different regions. To obtain the most up-to-date and accurate information, it is advisable to consult market reports and industry analyses from reputable sources. The majority of initial liver malignancies (78-88%) are hepatocellular carcinomas (HCCs). A substantial number of etiological variables of liver cancer, such as hepatitis infection and cirrhosis, are changeable and offer a good opportunity to lower its incidence and death by preventative methods such as lifestyle changes and hepatitis immunization. The greatest incidence and fatality ratios for liver cancer are seen in North America and Southern Europe. Male incidence rates varied significantly, with Eastern Asia (32.4 per 100,000) and South-Eastern Asia (23.6 per 100,000) having the highest rates. Female incidence rates were greatest in Eastern Asia (11.4 per 100,000) and Western Africa (9.3 per 100,000).

MARKET DYNAMICS

DRIVERS:

• Liver cancer is a major worldwide health problem, and its prevalence has been increasing in recent years. Chronic hepatitis B and C infections, increased obesity rates, excessive alcohol intake, and toxic exposure all contribute to the growing burden of liver cancer.

• A robust drug pipeline will help this market's growth opportunities.

Cancer research & development to deliver better patient treatment is advancing at a rapid pace. Innovative trials leading to combination therapy with new or existing pharmacological molecules have increased the number of candidates in the pipeline for liver cancer treatment. Furthermore, substantial support for R&D funding from the government and international healthcare organisations is projected to add to the liver cancer market potential. This, together with an increasing preference for biosimilars entering the market, is expected to boost market growth.

RESTRAIN:

• When liver cancer has gone beyond the liver, it is frequently discovered at an advanced stage. Treatment choices become restricted in such instances, and the efficacy of current medications may be diminished.

• Adverse drug effects and stringent regulations will limit market growth.

Treatment of cancer cells with a high dosage of medications results in tumour cell death and increased harm to normal body cells. Many people experience gastrointestinal problems, hair loss, exhaustion, skin problems, and other negative effects as a result of this. As a result, the adverse events associated with oncology treatments are having a negative impact on the growth of the global market for liver cancer drugs. Furthermore, regulatory authorities' tight requirements related to clinical trials are another factor impeding market expansion.

OPPORTUNITY:

• Despite advances in the treatment of liver cancer, there are still major unmet medical requirements. Improved therapeutics are needed, especially for advanced-stage liver cancer patients with few therapy options.

• The greatest opportunity in this sector is early detection and screening.

Early identification of liver cancer improves treatment results dramatically. There are opportunities to create and execute effective screening programmes, particularly for high-risk groups such people with chronic liver disease, hepatitis B or C infections, or cirrhosis. Diagnostic technology advancements, including imaging methods and biomarker discovery, can enhance early detection efforts and enable prompt therapies.

CHALLENGES:

• New liver cancer therapies are developed and approved through stringent regulatory processes that include clinical studies and regulatory filings. These procedures can be time-consuming, complicated, and expensive.

• In this market, limited therapeutic choices for advanced-stage liver cancer provide an obstacle.

Advanced-stage liver cancer, in which the illness has progressed beyond the liver, presents considerable therapeutic problems. Existing medicines may be ineffective in these advanced instances, and additional effective therapeutic options for late-stage liver cancer are needed.

IMPACT OF RUSSIAN UKRAINE WAR

As the conflict between Russia and Ukraine negatively impacts the pharmaceutical industry, Prominent pharmaceutical corporations have made multimillion-dollar donations to aid humanitarian operations in Ukraine. However, these corporations have conflicting feelings about continuing to do business with Russia. Hundreds of corporations, including airlines, banks, and internet behemoths, have left Russia in recent weeks. The U.S. has slapped various penalties on Russia in response to its invasion of Ukraine, but drugmakers, medical device manufacturers, and healthcare corporations have been excluded from these measures thus far. As a result, global pharmaceutical corporations have been hesitant to terminate operations in Russia, therefore they continue to manufacture and sell their goods there. However, several businesses have reduced their operations.

As a result, Russia has suffered a loss of 2-3% in the pharmaceutical sector and there has been an inflation in the Liver Cancer Therapeutics market in Russia.

IMPACT OF ONGOING RECESSION

Pharmaceutical and biotech firms rely on cross-industry & cross-departmental collaboration to create breakthrough medicines, improve patient care, and raise drug company profitability. Recession, defined as two consecutive quarters of negative GDP growth, can have a detrimental influence on population health since economic downturns are closely linked to lower healthcare usage and worsening health outcomes. Suicides and murders, for example, increased among working-age men and women in Europe during prior recessions. The number of uninsured non-elderly Americans increased by 5.2 million during the current recession, and about a quarter of Americans reported a decrease in regular medical care use. People's demand for health insurance has surged in recent years, and as a result, the continuing recession has had little influence on the Liver Cancer Therapeutics Market.

KEY MARKET SEGMENTATION

By Therapy Type

• Immunotherapy

• Targeted Drug Therapy

• Chemotherapy

By Distribution Channel

• Retail Pharmacy

• Hospital Pharmacy

• Online Pharmacy

Need any customization research on Liver Cancer Therapeutics Market - Enquiry Now

REGIONAL COVERAGE:

North America

• US

• Canada

• Mexico

Europe

• Eastern Europe

  • Poland

  • Romania

  • Hungary

  • Turkey

  • Rest of Eastern Europe

• Western Europe

  • Germany

  • France

  • UK

  • Italy

  • Spain

  • Netherlands

  • Switzerland

  • Austria

  • Rest of Western Europe

Asia Pacific

• China

• India

• Japan

• South Korea

• Vietnam

• Singapore

• Australia

• Rest of Asia Pacific

Middle East & Africa

• Middle East

  • UAE

  • Egypt

  • Saudi Arabia

  • Qatar

  • Rest of Middle East

• Africa

  • Nigeria

  • South Africa

  • Rest of Africa

Latin America

• Brazil

• Argentina

• Colombia

• Rest of Latin America

REGIONAL ANALYSIS

North America: The greatest market for liver cancer therapies is in North America, followed by Europe and Asia. The development of better healthcare infrastructure and the growing elderly population are driving the growth of the North American market. Because of the year-on-year growth in liver cancer diagnoses and the rising need for therapy, the United States leads the North American market. According to the American Society of Clinical Oncology, about 44,220 persons in the United States have been diagnosed with liver cancer. Early adoption of sophisticated technology diagnosis items and liver cancer procedures strengthens the region. The Canadian liver cancer treatment market is second only to the United States in terms of size.

Asia Pacific: Due to an ageing population, Asia-Pacific is the fastest-growing area for the liver cancer treatments market. Furthermore, an increase in the number of liver cancer patients in Asian nations is fuelling the market in this area. Other key factors contributing to APAC market growth include an increase in clinical research on liver illness, especially cancer, and an increase in the number of elderly persons. China is a potential place for industrial participants. The large base target population and critical unmet medical requirements enable the substantial market growth drive.

Key Players 

Some major key players in Liver Cancer Therapeutics Market are ImClone Systems Inc., Alnylam Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., Onyx Pharmaceuticals Inc., ArQule Inc., Pfizer Inc., Celsion Corp., Jennere Biotherapeutics Inc., 4SC AG, Bayer Schering Pharma AG, and other players.

Alnylam Pharmaceuticals Inc-Company Financial Analysis

RECENT DEVELOPMENT

F. Hoffmann-La Roche Ltd.: In 2021, F. Hoffmann-La Roche Ltd. reported updated overall survival statistics from the Phase III IMbrave150 research, which looked at the enhanced survival rate of liver cancer patients treated with Tecentrig and Avastin.

FDA: In 2020, The FDA authorised atezolizumab in conjunction with bevacizumab for the first-line treatment of liver cancer in the U.S.

F. Hoffmann-La Roche Ltd: In 2020, F. Hoffmann-La Roche Ltd. announced the European Commission (EU) clearance of Tecentriq in combination with Avastin for the treatment of liver cancer, with the goal of expanding the pharmaceutical range and increasing brand visibility in European nations.